Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 20/20 | 0.68 |
| ▸ | NR1H3 | Q13133 | 20/20 | 0.68 |
| ▸ | PPARG | P37231 | 3/20 | 0.62 |
| ▸ | PPARD | Q03181 | 2/20 | 0.62 |
| ▸ | PPARA | Q07869 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1126131 | 0.90 | NR1H2 (0.71) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL1125333 | 0.89 | NR1H2 (0.73) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL1124687 | 0.87 | NR1H2 (0.68) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL35403 | 0.87 | NR1H2 (0.75) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL27654054 | 0.87 | NR1H2 (0.68) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL1124869 | 0.87 | NR1H2 (0.83) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL1125422 | 0.86 | NR1H2 (0.60) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL1125215 | 0.85 | NR1H2 (0.66) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL4259266 | 0.85 | NR1H2 (0.69) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL1124771 | 0.85 | NR1H2 (0.66) | NR1H2NR1H3PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2284157-A1 | Quinolines useful in treating cardiovascular disease | Wyeth (US) | 2011-02-16 | — | — | EP | claimed |
| US-7576215-B2 | Quinolines and pharmaceutical compositions thereof | WYETH (US) | 2009-08-18 | — | — | US | claimed |
| US-7238679-B2 | Heterocycles and uses thereof | ARIAD PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | claimed |
| JP-2007516258-A | — | — | 2007-06-21 | — | — | JP | claimed |
| CN-1914173-A | Quinolines useful in treating cardiovascular disease | WYETH CORP (US) | 2007-02-14 | — | — | CN | claimed |
| EP-1692111-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | Wyeth, A Corporation of the State of Delaware (US) | 2006-08-23 | — | — | EP | claimed |
| WO-2005058834-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | WYETH (US) | 2005-06-30 | — | — | WO | claimed |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | WYETH (US) | 2005-06-16 | — | — | US | claimed |
| US-20040171586-A1 | Heterocycles and uses thereof | ARIAD PHARMACEUTICALS, INC. | 2004-09-02 | — | — | US | claimed |
| EP-2284157-A1 | Quinolines useful in treating cardiovascular disease | Wyeth (US) | 2011-02-16 | — | — | EP | disclosed |
| US-7576215-B2 | Quinolines and pharmaceutical compositions thereof | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| EP-2074098-A2 | QUINOLINE COMPOUNDS | Wyeth (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090069373-A1 | Quinoline Acids | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2008049047-A2 | QUINOLINE COMPOUNDS | WYETH (US) | 2008-04-24 | — | — | WO | disclosed |
| US-7132427-B2 | Quinazolines and uses thereof | ARIAD PHARMACEUTICALS, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1692111-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | Wyeth, A Corporation of the State of Delaware (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005058834-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | WYETH (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
| US-20040171586-A1 | Heterocycles and uses thereof | ARIAD PHARMACEUTICALS, INC. | 2004-09-02 | — | — | US | disclosed |
| US-20030100573-A1 | Novel quinazolines and uses thereof | ARIAD PHARMACEUTICALS, INC. | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100573-A1 | Novel quinazolines and uses thereof | UQCRB, NQO2, RAB7A | NR1H2 812/4885NR1H3 751/4885PPARG 4113/4885 |
| US-20090069373-A1 | Quinoline Acids | NR1H3, NR1H2, NR1H4 | NR1H2 2/4885NR1H3 1/4885PPARG 37/4885 |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | NR1H2, NR1H3, SREBF1 | NR1H2 1/4885NR1H3 2/4885PPARG 38/4885 |
| US-20040171586-A1 | Heterocycles and uses thereof | CBR1, CBR3, RCOR1 | NR1H2 120/4885NR1H3 135/4885PPARG 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.